Pearson's correlation (r) between measures of left vent

Hormone therapy with tamoxifen reduces plasma levels of NT-B-type natriuretic peptide but does not change ventricular ejection fraction after chemotherapy in women with breast cancer. Silva FB, Romero WG, Carvalho AL, Borgo MV, Amorim MH, Gouvea SA, Abreu GR - Braz. J. Med. Biol. Res. (2014) Bottom Line: At T12, the chemotherapy + tamoxifen group exhibited a significant reduction in the peptide to levels similar to the group that received tamoxifen alone.The chemotherapy-only group exhibited a significant decrease in LVEF at T12, whereas the chemotherapy + tamoxifen and tamoxifen-only groups maintained levels similar to those at the beginning of treatment.Treatment with tamoxifen for 6 months after chemotherapy significantly reduced the plasma levels of NT-proBNP and did not change LVEF in women with breast cancer. View Article: PubMed Central - PubMed Affiliation: Departamento de Ciências Fisiológicas, Centro de Ciências da Saúde, Universidade Federal do Espírito Santo, Vitória, ES, Brasil. ABSTRACT The objective of this study was to evaluate the effect of tamoxifen on the plasma concentration of NT-pro-B-type natriuretic peptide (NT-proBNP) in women undergoing chemotherapy for breast cancer and to correlate changes in NT-proBNP with the left ventricular ejection fraction (LVEF). Over a period of 12 months, we followed 60 women with a diagnosis of breast cancer. The patients were separated into a group that received only chemotherapy (n=23), a group that received chemotherapy + tamoxifen (n=21), and a group that received only tamoxifen (n=16). Plasma levels of NT-proBNP were assessed at 0 (T0), 6 (T6), and 12 (T12) months of treatment, and echocardiography data were assessed at T0 and T12. Plasma NT-proBNP levels were increased in the chemotherapy-only group at T6 and T12, whereas elevated NT-proBNP levels were only found at T6 in the chemotherapy + tamoxifen group. At T12, the chemotherapy + tamoxifen group exhibited a significant reduction in the peptide to levels similar to the group that received tamoxifen alone. The chemotherapy-only group exhibited a significant decrease in LVEF at T12, whereas the chemotherapy + tamoxifen and tamoxifen-only groups maintained levels similar to those at the beginning of treatment. Treatment with tamoxifen for 6 months after chemotherapy significantly reduced the plasma levels of NT-proBNP and did not change LVEF in women with breast cancer. Show MeSH Major Antineoplastic Agents, Hormonal/therapeutic use* Breast Neoplasms/drug therapy* Natriuretic Peptide, Brain/blood* Peptide Fragments/blood* Stroke Volume/drug effects* Tamoxifen/therapeutic use* Minor Adult Analysis of Variance Biomarkers/blood Chemotherapy, Adjuvant Cyclophosphamide/therapeutic use Doxorubicin/therapeutic use Echocardiography Female Fluorouracil/therapeutic use Follow-Up Studies Humans Middle Aged Paclitaxel/therapeutic use Statistics as Topic Related in: MedlinePlus	$Pearson's correlation (r) between measures of left ventricular ejectionfraction (LVEF) and pro-B-type natriuretic peptide (proBNP) in the groupstreated with chemotherapy alone (A), chemotherapy followedby tamoxifen (B), and tamoxifen alone(C).$ © Copyright Policy - open-access Related In: Results - Collection License Show All Figures getmorefigures.php?uid=PMC4321221&req=5 f04: Pearson's correlation (r) between measures of left ventricular ejectionfraction (LVEF) and pro-B-type natriuretic peptide (proBNP) in the groupstreated with chemotherapy alone (A), chemotherapy followedby tamoxifen (B), and tamoxifen alone(C). Mentions: Pearson's correlation analysis showed a strong negative correlation (-0.77,P<0.01) between LVEF and plasma NT-proBNP levels in the chemotherapy group(Figure 4A) at T12. However, the negativecorrelation between LVEF and NT-proBNP levels in the chemotherapy + tamoxifen(Figure 4B) and tamoxifen-only (Figure 4C) groups was weak (-0.29 and -0.05,respectively), which is consistent with the finding that neither LVEF norNT-proBNP differed significantly in those groups at T12.

Hormone therapy with tamoxifen reduces plasma levels of NT-B-type natriuretic peptide but does not change ventricular ejection fraction after chemotherapy in women with breast cancer.

Silva FB, Romero WG, Carvalho AL, Borgo MV, Amorim MH, Gouvea SA, Abreu GR - Braz. J. Med. Biol. Res. (2014)

Bottom Line: At T12, the chemotherapy + tamoxifen group exhibited a significant reduction in the peptide to levels similar to the group that received tamoxifen alone.The chemotherapy-only group exhibited a significant decrease in LVEF at T12, whereas the chemotherapy + tamoxifen and tamoxifen-only groups maintained levels similar to those at the beginning of treatment.Treatment with tamoxifen for 6 months after chemotherapy significantly reduced the plasma levels of NT-proBNP and did not change LVEF in women with breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Departamento de Ciências Fisiológicas, Centro de Ciências da Saúde, Universidade Federal do Espírito Santo, Vitória, ES, Brasil.

ABSTRACT

The objective of this study was to evaluate the effect of tamoxifen on the plasma concentration of NT-pro-B-type natriuretic peptide (NT-proBNP) in women undergoing chemotherapy for breast cancer and to correlate changes in NT-proBNP with the left ventricular ejection fraction (LVEF). Over a period of 12 months, we followed 60 women with a diagnosis of breast cancer. The patients were separated into a group that received only chemotherapy (n=23), a group that received chemotherapy + tamoxifen (n=21), and a group that received only tamoxifen (n=16). Plasma levels of NT-proBNP were assessed at 0 (T0), 6 (T6), and 12 (T12) months of treatment, and echocardiography data were assessed at T0 and T12. Plasma NT-proBNP levels were increased in the chemotherapy-only group at T6 and T12, whereas elevated NT-proBNP levels were only found at T6 in the chemotherapy + tamoxifen group. At T12, the chemotherapy + tamoxifen group exhibited a significant reduction in the peptide to levels similar to the group that received tamoxifen alone. The chemotherapy-only group exhibited a significant decrease in LVEF at T12, whereas the chemotherapy + tamoxifen and tamoxifen-only groups maintained levels similar to those at the beginning of treatment. Treatment with tamoxifen for 6 months after chemotherapy significantly reduced the plasma levels of NT-proBNP and did not change LVEF in women with breast cancer.

Show MeSH

Related in: MedlinePlus

$Pearson's correlation (r) between measures of left ventricular ejectionfraction (LVEF) and pro-B-type natriuretic peptide (proBNP) in the groupstreated with chemotherapy alone (A), chemotherapy followedby tamoxifen (B), and tamoxifen alone(C).$

Related In: Results - Collection

License

Show All Figures

getmorefigures.php?uid=PMC4321221&req=5

f04: Pearson's correlation (r) between measures of left ventricular ejectionfraction (LVEF) and pro-B-type natriuretic peptide (proBNP) in the groupstreated with chemotherapy alone (A), chemotherapy followedby tamoxifen (B), and tamoxifen alone(C).

Mentions: Pearson's correlation analysis showed a strong negative correlation (-0.77,P<0.01) between LVEF and plasma NT-proBNP levels in the chemotherapy group(Figure 4A) at T12. However, the negativecorrelation between LVEF and NT-proBNP levels in the chemotherapy + tamoxifen(Figure 4B) and tamoxifen-only (Figure 4C) groups was weak (-0.29 and -0.05,respectively), which is consistent with the finding that neither LVEF norNT-proBNP differed significantly in those groups at T12.